Literature DB >> 26654096

Robotic Partial Nephrectomy in the Treatment of Renal Angiomyolipoma.

Onder Kara1, Oktay Akca1, Homayoun Zargar1, Hiury Silva Andrade1, Matthew Joseph Maurice1, Daniel Ramirez1, Peter Caputo1, George-Pascal Haber1, Jihad H Kaouk1, Robert J Stein1.   

Abstract

PURPOSE: To present the experience and efficacy of Robotic Partial Nephrectomy (RPN) for the management of renal angiomyolipomas (AMLs) with regard to renal function preservation and perioperative outcomes. PATIENTS AND METHODS: We retrospectively searched our RPN database for pathologically confirmed renal AML patients between 2006 and 2014. Clinical presentation, perioperative complications, and postoperative outcomes of the patients were analyzed. Preoperative imaging findings were reviewed to examine their ability to predict pathology of AML.
RESULTS: From 1005 RPN performed in our center during the study period, 53 patients met our inclusion criteria. The mean age at presentation was 54.1 (± 13) years, and 42 (79.2%) patients were female. Median tumor size was 2.8 (interquartile range [IQR], 1.8-4.6) cm. The indication for RPN was suspicious radiologic features for malignancy in 42 (79.2%) patients and acute retroperitoneal hemorrhage risk and pain in 11 (20.8%) patients who were found to have AML according to preoperative imaging. Mean estimated blood loss was 198 (± 194) mL, and 5 (9.4%) patients required blood transfusion. Postoperative complications occurred in 8 (15%) patients. Median estimated glomerular filtration rate within the latest follow-up was 86.9 (IQR, 69.7-100.1) mL/minute/1.73 m(2) with a median of 91% (IQR, 80.4-103) preservation. None of patients developed urinary fistula or pseudoaneurysm requiring second intervention. No local recurrences occurred with a median follow-up of 7 (IQR, 1-17) months.
CONCLUSION: Given the low complication rate and preservation of renal function after RPN for AML, it can be considered a reliable method for AML treatment. The majority of AMLs were not suspected based on preoperative imaging. Further diagnostic methods are needed to differentiate benign from malignant lesions.

Entities:  

Mesh:

Year:  2015        PMID: 26654096     DOI: 10.1089/end.2015.0624

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  7 in total

1.  Selective arterial embolization of renal angiomyolipomas: A 10-year experience.

Authors:  Guram Nozadze; Signe Benzon Larsen; Søren Heerwagen; Ruben Juhl Jensen; Lars Lönn; Martin Andreas Røder
Journal:  BJUI Compass       Date:  2021-08-31

Review 2.  [What can/should be treated in kidney tumors and when].

Authors:  C M Sommer; D F Vollherbst; G M Richter; H U Kauczor; P L Pereira
Journal:  Radiologe       Date:  2017-02       Impact factor: 0.635

3.  Retroperitoneal extrarenal angiomyolipoma at the surgical bed 8 years after a renal angiomyolipoma nephrectomy: A case report and review of literature.

Authors:  Anugayathri Jawahar; Joao Kazan-Tannus
Journal:  Urol Ann       Date:  2017 Jul-Sep

Review 4.  The Risks of Renal Angiomyolipoma: Reviewing the Evidence.

Authors:  Raouf M Seyam; Waleed K Alkhudair; Said A Kattan; Mohamed F Alotaibi; Hassan M Alzahrani; Waleed M Altaweel
Journal:  J Kidney Cancer VHL       Date:  2017-10-16

5.  Robot-Assisted versus Laparoscopic Partial Nephrectomy for Giant Sporadic Renal Angiomyolipomas of ≥7 cm: A Propensity Score-Matched Analysis.

Authors:  Yunqiang Xiong; Wen Deng; Ru Chen; Xiaoqiang Liu; Ke Zhu; Jiayao Wang; Jiahui Long; Haoxin Jiang; Luyao Chen; Bin Fu
Journal:  J Oncol       Date:  2021-08-26       Impact factor: 4.375

6.  Benign Neoplasm of Kidney: Angiomyolipoma.

Authors:  Shih-Feng Wang; Wah-On Lo
Journal:  J Med Ultrasound       Date:  2018-09-14

7.  Robotic-assisted partial nephrectomy with sequential clamping of segmental renal arteries for multiple ipsilateral renal tumors: initial outcomes.

Authors:  Jie Yang; Jia-Dong Xia; Jian-Xin Xue; Ning-Hong Song; Chao Liang; Di Xi; Ya-Min Wang; Zeng-Jun Wang
Journal:  BMC Urol       Date:  2019-05-03       Impact factor: 2.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.